Australia's ReNerve rises on Malaysian approval for its NervAlign product
14/01/2026 23:59
** Shares of ReNerve RNV.AX rise as much as 30% to A$0.130, their highest levels since November 24 ** Stock marks its biggest intraday pct gain since November 13 ** The medical device innovator receives market registration approval in Malaysia for its NervAlign Nerve Cuff ** Adds that product is used in peripheral nerve repair, offering precise solution for supporting nerve regeneration ** Stock lost over 40% in 2025 (Reporting by Rajasik Mukherjee in Bengaluru) ((Rajasik.Mukherjee@thomsonreuters.com))
Recent news on Renerve
See all newsBrief: Renerve Says Positive FDA Feedback On Nervalign Nerve Guide Matrix
Brief: Renerve And Rmit Awarded A$499K Grant
Brief: ReNerve Posts Full-Year Loss Attributable Of A$5.6 Million
Brief: ReNerve Says Nervalign Nerve Cuff Receives CDSCO Marketing Approval In India
Australia's ReNerve rises on securing up to A$5 million funding facility